By Darrin LaVelle, Founder of RENVA Health
Last updated: July 3, 2026
Short answer: most people who stop GLP-1 medications regain a substantial share of the weight they lost, generally starting within weeks and continuing over the following year. This isn't a personal failure — it reflects how these medications work and how the body responds when that mechanism is removed.
If you're considering starting a GLP-1 medication, or wondering what happens if you eventually need to stop one, this walks through what the research actually shows — the numbers, why regain happens, and what's known about ways to manage the transition.
The STEP-1 trial itself found that participants taking semaglutide lost an average of 17.3% of their starting body weight by week 68, compared to 2.0% in the placebo group. A follow-up extension study tracked 327 of those participants after they stopped taking semaglutide and stopped the structured lifestyle program that came with the trial.
By one year after stopping — week 120 of the study overall — participants had regained an average of 11.6 percentage points of the weight they'd lost. That left a net loss of 5.6% from their original starting weight, meaning roughly two-thirds of their total weight loss had returned within a year of discontinuing.
SURMOUNT-4 took a more controlled approach to studying this question. After 670 participants lost an average of 20.9% of their body weight over 36 weeks on tirzepatide, they were split into two groups: one continued the medication, the other switched to a placebo, for the next 52 weeks.
The results were a clear contrast. Those who continued tirzepatide lost an additional 5.5% of body weight. Those switched to placebo regained about 14% — roughly half of what they'd originally lost. A more detailed follow-up analysis found that 82% of the placebo group had regained at least a quarter of their lost weight within a year, though a smaller subgroup regained less than 25%, suggesting individual response to discontinuation varies.
A 2026 systematic review pooled data from 37 studies covering more than 9,300 adults who had stopped various weight-management medications, following them for an average of 32 weeks after stopping. Across all medications studied, weight increased by an average of 0.9 lb per month after stopping, with projections suggesting a return to starting weight within 1.5 to 2 years for the average person.
For GLP-1 medications specifically (semaglutide and tirzepatide), the regain was somewhat faster — an average of 1.8 lb per month — with models projecting a return to baseline weight around the 1.5-year mark, though the researchers noted that reliable data beyond 12 months off the medication is still limited. Notably, this same analysis found that regain after stopping medication happens measurably faster than regain after ending a purely behavioral (diet and exercise) program — evidence that these drugs are doing something pharmacologically specific that isn't simply replaced by willpower once it's withdrawn.
This is the part that's often left out of the conversation, and it matters: weight regain after stopping a GLP-1 medication isn't a sign that the treatment "didn't work" or that someone did something wrong. It's a predictable, mechanistic result of how these drugs function.
GLP-1 and dual GIP/GLP-1 medications work partly by strengthening the brain's fullness signals, slowing digestion, and shifting the balance between hunger and satiety hormones. While someone is on the medication, this creates an ongoing pharmacological effect that makes it easier to eat less. When the medication is stopped, that effect is removed — hunger signals increase, satiety diminishes, and eating patterns that existed before treatment tend to re-emerge, often without the person consciously "deciding" anything has changed.
Researchers involved in the STEP-1 extension study put it plainly: obesity is a chronic, relapsing condition, and their findings "confirm the chronicity of obesity" — meaning ongoing treatment, not a fixed course of it, is generally what's required to maintain results. Investigators studying the SURMOUNT-4 data used a direct comparison: obesity behaves like other chronic conditions such as high blood pressure or type 2 diabetes, where stopping effective treatment predictably leads to the return of the condition being treated.
Weight isn't the only thing that reverses after stopping these medications. In the STEP-1 extension, improvements seen during treatment — blood pressure, cholesterol markers, blood sugar control, and inflammation markers — all trended back toward pre-treatment baseline over the year following discontinuation, tracking closely with how much weight came back.
The SURMOUNT-4 data showed a similar pattern in more granular detail: people who regained more weight after stopping tirzepatide saw correspondingly larger increases in waist circumference, cholesterol, and blood insulin levels than those who regained less. The 2026 meta-analysis estimated that, on average, cardiometabolic markers that improved during treatment would return to baseline within roughly 1.4 years of stopping.
The takeaway isn't that these improvements were temporary or fake — they were real while the medication was active. It's that they were tied to the ongoing treatment, similar to how blood pressure improvements from a blood pressure medication don't persist if someone stops taking it.
If stopping a GLP-1 medication becomes necessary — due to side effects, cost, pregnancy, access issues, or personal choice — there isn't yet a standardized, universally proven approach to minimize regain. That said, a few strategies are discussed in current medical literature:
Some ongoing research is also exploring whether switching from an injectable medication to a newer oral GLP-1 option can help sustain weight loss after stopping the original injectable — but this is still under study, not an established practice as of this writing.
Importantly, there is currently no separate medication FDA-approved specifically for "maintaining weight after stopping a GLP-1" — the options are generally either continuing GLP-1-class treatment long-term, or working with a prescriber on an individualized plan that may include other weight-management medications or an intensified behavioral approach.
None of this is a reason to avoid GLP-1 medications if they're appropriate for you — the weight loss and health improvements documented in the trials referenced here are real and clinically significant. What the data does suggest is that these medications work best when approached as a long-term or indefinite commitment, similar to how you'd think about treatment for a chronic condition, rather than a short course meant to produce a permanent result on its own.
If you're weighing whether to start, it's worth having a direct conversation with a prescriber about what the plan looks like if you eventually need to pause or stop — rather than treating that as a decision to figure out later.
Q: Will I regain all the weight I lost if I stop?
Not necessarily all of it, but the data suggests most people regain a substantial portion — roughly half to two-thirds of lost weight within a year, based on the trials referenced above. Individual results vary, and some people maintain more of their loss than others.
Q: How quickly does weight regain start after stopping?
Research suggests it begins fairly soon after discontinuation and continues over months, with most of the regain happening within the first year, though it can continue somewhat longer.
Q: Do the blood sugar and cholesterol improvements also go away?
Largely, yes — cardiometabolic improvements tend to track weight regain, gradually trending back toward pre-treatment levels as weight returns, based on both the STEP-1 extension and SURMOUNT-4 data.
Q: Is tapering off the medication better than stopping abruptly?
This is discussed as a possible strategy in medical literature, but there isn't yet strong trial evidence proving it reduces regain. Any tapering approach should be planned with a prescriber, not self-directed.
Q: Does this mean I'll need to be on a GLP-1 medication forever?
Not necessarily "forever," but the research supports viewing these medications as a long-term or ongoing treatment for a chronic condition, similar to how blood pressure or diabetes medications are used — rather than a fixed-length course. Whether and when to stop is a decision to make with a prescriber based on your individual situation.
See also: What Is a GLP-1 Medication? for a plain-language explanation of how this drug class works, and How Long Does It Take for GLP-1 Medications to Work? for what the week-by-week timeline actually looks like.
If you're struggling with thoughts about your weight, eating, or body image, you're not alone, and support is available. The National Alliance for Eating Disorders helpline can help connect you with resources.
Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →
Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.
Take the free quizGLP-1 medications explained in plain language: what they are, how they work in your gut and brain, and what the research shows about weight loss results.
Tirzepatide activates one more hormone receptor than semaglutide — and across every major trial, that difference shows up as more average weight loss.
Oral GLP-1 pills have closed much of the gap with weekly injections. Here's how the two approaches compare on results, convenience, and what the trial data actually shows.